Literature DB >> 31503225

Evaluation of Gabapentin and Clonidine Use in Children Following Spinal Fusion Surgery for Idiopathic Scoliosis: A Retrospective Review.

Dinesh K Choudhry1, B Randall Brenn1, Karen Sacks1, Suken Shah2.   

Abstract

BACKGROUND: Opioids are the mainstay of therapy for pain relief following posterior spinal fusion (PSF) surgery. Various adjunctive medications are being used to augment analgesia and to reduce opioid-related side effects. At our institution, we have sequentially added 2 adjuncts to a standard morphine patient-controlled analgesia (PCA) regimen. The goal of our study was to evaluate pain control and the benefit of gabapentin and the combination of gabapentin and clonidine, whereas morphine PCA was in use in children following PSF surgery.
METHODS: Following Institutional Review Board approval, data were collected retrospectively from the charts of 127 patients who underwent PSF for idiopathic scoliosis. Children were divided into the 3 following groups: group P, morphine PCA only (42 patients), group G, morphine PCA+gabapentin (45 patients), and group C, morphine PCA+gabapentin+clonidine (40 patients).
RESULTS: Addition of gabapentin to our regimen improved the outcome, but the addition of transdermal clonidine and gabapentin together were found to be significantly better in some aspects. Children in group G and C used less morphine on postoperative day 1 following surgery, had more PCA demand-free hours, were able to take orals, were able to ambulate sooner, and had a shorter hospital stay than group P. There were no differences in side effects or sedation between the 3 groups.
CONCLUSIONS: In conclusion, additions of postoperative transdermal clonidine and perioperative oral gabapentin together were found to improve functional outcomes following PSF surgery. Group G and C had reduced opioid use and shorter hospital stay than group P. Addition of these adjuncts together was found to be better since group C patients made fewer PCA attempts to obtain morphine over the first 10-hour period postoperatively and were able to ambulate sooner than group G. The PCA pump usage pattern provides useful information about patient comfort and efficacy of adjunctive medications. LEVEL OF EVIDENCE: Level II-retrospective study.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31503225     DOI: 10.1097/BPO.0000000000000989

Source DB:  PubMed          Journal:  J Pediatr Orthop        ISSN: 0271-6798            Impact factor:   2.324


  5 in total

1.  Effectiveness of gabapentin as a postoperative analgesic in children undergoing appendectomy.

Authors:  Katherine J Baxter; Jennifer Hafling; Jennifer Sterner; Adarsh U Patel; Helen Giannopoulos; Kurt F Heiss; Mehul V Raval
Journal:  Pediatr Surg Int       Date:  2018-05-04       Impact factor: 1.827

Review 2.  Postoperative pain management in patients undergoing posterior spinal fusion for adolescent idiopathic scoliosis: a narrative review.

Authors:  Hiroyuki Seki; Satoshi Ideno; Taiga Ishihara; Kota Watanabe; Morio Matsumoto; Hiroshi Morisaki
Journal:  Scoliosis Spinal Disord       Date:  2018-09-12

3.  Current Trends in Pediatric Spine Deformity Surgery: Multimodal Pain Management and Rapid Recovery.

Authors:  Sagar A Shah; Richard Guidry; Abhishek Kumar; Tyler White; Andrew King; Michael J Heffernan
Journal:  Global Spine J       Date:  2019-09-22

4.  Gabapentin and intrathecal morphine combination therapy results in decreased oral narcotic use and more consistent pain scores after posterior spinal fusion for adolescent idiopathic scoliosis.

Authors:  Ying Li; Jennylee Swallow; Christopher Robbins; Michelle S Caird; Aleda Leis; Rebecca A Hong
Journal:  J Orthop Surg Res       Date:  2021-11-15       Impact factor: 2.359

5.  Lidocaine as an element of multimodal analgesic therapy in major spine surgical procedures in children: a prospective, randomized, double-blind study.

Authors:  Ilona Batko; Barbara Kościelniak-Merak; Przemysław J Tomasik; Krzysztof Kobylarz; Jerzy Wordliczek
Journal:  Pharmacol Rep       Date:  2020-04-15       Impact factor: 3.024

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.